Popular beliefs frame testosterone as purely immune-suppressing, but clinical evidence demonstrates that androgens delicately balance both innate and adaptive cellular responses.
Imagine sitting in a doctor's office or reading online forums after receiving blood test results. You notice your testosterone is on the lower end of the reference range. At the same time, you have dealt with frequent seasonal colds, persistent fatigue, or lingering joint aches. It is tempting to connect these dots and wonder if your hormone levels are directly weakening your body's defense network.
Online discussions often present extreme views on this topic. Some marketing claims promote hormone therapy as a way to supercharge immune defenses. Other sources claim that male sex hormones actively suppress immunity and leave men vulnerable to infections. The scientific reality is far more nuanced.
This resource breaks down what peer-reviewed research actually shows about androgen signaling, inflammation, and immune function. It explains why laboratory discoveries in cell cultures do not automatically translate into clinical treatments. Most importantly, it outlines the clear clinical boundaries established by professional medical societies.
This article is published strictly for educational and informational purposes. It does not constitute individual medical advice, diagnosis, or treatment recommendations. Hormone replacement therapy involves complex physiological pathways and potential health risks that require direct evaluation by a qualified healthcare professional. Always consult a licensed clinician regarding any medical condition, laboratory test, or treatment plan.
To understand how hormones interact with immune defenses, it is necessary to examine androgen biology. Testosterone is the primary circulating male sex hormone, produced mainly by Leydig cells in the testes and in smaller quantities by the adrenal glands. Once in circulation, testosterone can exert direct effects, but it is also converted locally within peripheral tissues into other active signaling molecules.
The enzyme 5-alpha reductase converts testosterone into dihydrotestosterone (DHT), a significantly more potent androgen. Concurrently, the aromatase enzyme converts a fraction of circulating testosterone into estradiol, the primary female sex hormone. Because many immune cells express receptors for both androgens and estrogens, local hormone metabolism directly shapes cellular activity. When researchers evaluate hormone exposure in a tissue, the measured response often reflects this combined hormonal milieu rather than the action of testosterone in isolation.
Androgens primarily act through the androgen receptor (AR). When testosterone or DHT binds to an intracellular androgen receptor, the complex undergoes structural changes and translocates to the cell nucleus. Inside the nucleus, it acts as a transcription factor, binding to specific DNA sequences known as androgen response elements. This classical genomic pathway regulates the expression of hundreds of genes, including those involved in cellular growth, cytokine production, and receptor development.
Beyond this classical genomic mechanism, androgens can also trigger non-genomic signaling pathways. These rapid actions occur via membrane-bound or cytoplasmic receptors, initiating intracellular calcium flux and kinase cascades within seconds or minutes. Through these combined mechanisms, androgen signaling influences both the development of immature immune-cell precursors in the bone marrow and thymus, as well as the behavior of mature immune cells circulating in the bloodstream. Readers interested in broader physiological mechanics can review our guide on testosterone fundamentals and hormonal function.
In popular media, hormones are often described as either immune boosters or immune suppressors. Scientific literature avoids this binary framing. Researchers classify androgens as immunomodulators because they adjust, calibrate, and shape immune activity rather than shutting it down or accelerating it across the board.
The immune system requires a delicate balance between active defense and self-regulation. To evaluate scientific claims accurately, you must distinguish between three distinct concepts:
A laboratory finding showing that testosterone alters a single inflammatory chemical does not prove that a person's overall immune competence has improved or declined. Similarly, a shift in a biological marker does not automatically lead to a better clinical outcome.
Navigating health science requires a clear method for evaluating the strength of different types of evidence. In hormone and immunology research, confusing a test-tube observation with clinical proof is a common mistake. Scientists use an evidence hierarchy to determine whether a biological concept applies safely to patient care.
At the base of this hierarchy are cell cultures and animal models. These mechanistic studies allow researchers to isolate specific receptors and observe molecular pathways in controlled environments. For instance, scientists can expose isolated white blood cells to varying concentrations of testosterone and measure changes in gene expression. These studies are essential for discovering potential biological pathways, but they cannot account for the complexity of a living human body.
The second tier consists of human biomarker studies. In these trials, researchers administer a hormone and measure circulating proteins, such as cytokines or antibodies. While these studies show that a biological interaction occurs in humans, biomarkers are surrogate endpoints. A decrease in a pro-inflammatory marker in a blood sample does not prove that a patient will experience fewer sick days or recover faster from a virus.
The third tier includes observational and epidemiological studies. These investigations observe health patterns across large populations over time, noting correlations between natural hormone levels and disease incidence. While valuable for generating hypotheses, observational studies cannot establish cause and effect. A correlation between low testosterone and poor health outcomes may simply reflect the fact that chronic illness lowers hormone levels, rather than the reverse.
Randomized controlled trials (RCTs) represent the fourth tier and provide the strongest causal evidence. In an RCT, participants are randomly assigned to receive either an active treatment or an inactive placebo under blinded conditions. This design balances unknown confounding factors between groups, allowing researchers to determine whether the intervention directly caused the observed health outcome.
At the top of the ladder sit guideline-supported clinical recommendations developed by professional medical consensus panels, such as the Endocrine Society. These guidelines synthesize evidence across multiple high-quality RCTs, balancing treatment benefits against documented risks. Clinical decisions regarding hormone therapy must rest on this top tier of validated evidence rather than exploratory laboratory data.
The innate immune system serves as the body's first line of defense against invading pathogens. It acts rapidly and non-specifically, utilizing physical barriers, specialized white blood cells, and chemical signaling proteins. A major 2024 scientific review on androgens and immune-cell function outlines several key pathways through which male hormones interact with innate immune cells.
Monocytes are circulating white blood cells that migrate into tissues and differentiate into macrophages. Macrophages act as cellular scavengers, engulfing pathogens, clearing cellular debris, and releasing signaling molecules that orchestrate the broader inflammatory response.
Laboratory investigations demonstrate that macrophages express functional androgen receptors. In multiple experimental models, exposing stimulated macrophages to testosterone increases the production of interleukin-10 (IL-10), a potent anti-inflammatory cytokine. Concurrently, androgen exposure has been shown to reduce macrophage production of nitric oxide and pro-inflammatory signaling proteins, such as tumor necrosis factor alpha (TNF-alpha).
However, cellular responses are highly dependent on the inflammatory context. Some laboratory experiments show that under specific stimulation, testosterone can increase the expression of interleukin-6 (IL-6) genes in macrophages. This variability demonstrates why describing testosterone as purely anti-inflammatory is an oversimplification. The hormone's effect depends directly on the specific inflammatory signals present in the surrounding tissue.
Neutrophils are the most abundant type of white blood cell in human circulation, responding rapidly to bacterial and fungal infections. They neutralize threats by engulfing pathogens through a process called phagocytosis, releasing antimicrobial enzymes, and producing reactive oxygen species.
Research indicates that neutrophil responses to androgens are highly dose-dependent. In controlled laboratory settings, exposing neutrophils to physiological concentrations of testosterone (such as 10 nanomoles per liter) enhanced their phagocytic capacity. Conversely, exposing the same cells to supraphysiological concentrations (such as 10 micromoles per liter) significantly reduced their microbicidal activity.
These experimental findings illustrate an essential scientific principle: cellular responses change dramatically across different hormone concentrations. High concentrations used in laboratory assays cannot be interpreted as recommendations for clinical dosing or hormone supplementation.
Dendritic cells function as critical messengers between the innate and adaptive immune systems. They capture foreign antigens, process them, and present them on their cell surface to activate naive T cells.
Current scientific literature regarding androgen action in dendritic cells remains limited and unresolved. Different studies have reported conflicting findings regarding the presence and density of androgen receptors on dendritic cells. Furthermore, reported cellular responses vary widely depending on how the cells were prepared and the specific chemical stimuli applied in the laboratory. Because evidence is currently inconclusive, researchers consider androgen signaling in dendritic cells an active area of basic science rather than an established clinical pathway.
While the innate immune system acts immediately, the adaptive immune system provides targeted, pathogen-specific defense and creates long-lasting immunological memory. Adaptive immunity relies on two primary lymphocyte classes: T cells and B cells.
T cells develop in the bone marrow and mature in the thymus gland. They differentiate into several specialized subsets, including CD4+ helper T cells, CD8+ cytotoxic killer T cells, and regulatory T cells (Tregs). Helper T cells coordinate immune responses by releasing cytokines, while cytotoxic T cells directly destroy infected or cancerous cells. Regulatory T cells play an essential role in preventing autoimmune disease by suppressing excessive immune reactions.
Androgen signaling influences T cells at multiple stages of their life cycle:
These mechanistic patterns help explain why autoimmune conditions that feature overactive Th1 and Th17 pathways, such as multiple sclerosis and rheumatoid arthritis, occur far more frequently in women than in men. However, while androgens appear to provide a biological buffer against certain autoimmune pathways, this physiological difference does not mean testosterone therapy can be used as a standard medical treatment for established autoimmune diseases.
B cells are responsible for humoral immunity, producing targeted antibodies that neutralize pathogens and mark them for destruction. The interaction between androgens and B cells occurs primarily during early cellular development.
Androgen receptors are expressed abundantly on early B-cell precursors within the bone marrow. Signaling through these receptors regulates B-cell lymphopoiesis, modulating the total number of mature B cells released into peripheral circulation. Once B cells mature and migrate into lymph nodes and the spleen, their expression of androgen receptors declines significantly.
This biological distinction prevents a common misunderstanding. Popular health articles sometimes claim that testosterone directly shuts down antibody production in adults. While experimental laboratory models show that high concentrations of androgens can inhibit immunoglobulin secretion in isolated peripheral blood mononuclear cells, mature circulating B cells do not respond in the same uniform manner as developing precursors. Clinical trials evaluating vaccine efficacy show that men with normal physiological testosterone levels maintain robust, protective antibody responses following vaccination. For a deeper look at emerging hormone science, visit our section on TRT and emerging research.
Translating laboratory cell models into human clinical trials is where biological hypotheses face their true test. While mechanistic studies suggest that testosterone modulates immune signaling, human trials provide a much clearer picture of what actually occurs in the body.
One of the most frequently cited human studies investigating testosterone and immune signaling was conducted by Dr. Philip Malkin and his research colleagues in 2004. This clinical trial evaluated the short-term effects of testosterone replacement on circulating inflammatory cytokines.
The trial enrolled 27 men with a mean age of 62 years who had symptomatic androgen deficiency and confirmed low baseline total testosterone. The study utilized a randomized, single-blind, placebo-controlled crossover design:
The researchers measured changes in circulating cytokine levels in the participants' blood. The results showed notable chemical shifts:
This study proved that restoring testosterone to normal levels in men with diagnosed deficiency can alter specific circulating cytokines over a four-week period. However, the trial was small, short in duration, and measured only surrogate biochemical markers. It did not track infection rates, immune resilience, or long-term clinical health outcomes.
To determine whether these cytokine shifts persist over extended periods, researchers must examine long-term clinical trials. A key analysis published in conjunction with the landmark Testosterone Trials evaluated systemic inflammatory markers over a 36-month period of transdermal testosterone treatment in older men with low testosterone.
In contrast to the short-term findings of the Malkin study, this long-term analysis demonstrated that 36 months of continuous testosterone therapy did not produce a statistically significant reduction in circulating inflammatory markers compared to placebo.
This contrast between short-term and long-term human data provides a vital lesson in medical science. A temporary shift in a blood biomarker during a four-week trial does not guarantee a permanent change in systemic inflammation or immune function over several years. Biological systems frequently adapt, recalibrate, and establish new homeostatic balances over time.
The global COVID-19 pandemic generated intense scientific interest in the relationship between sex hormones and viral immune responses. Early clinical data quickly revealed that men faced higher rates of severe illness, intensive care admission, and mortality compared to women of similar age. This observation led researchers to explore two opposing hypotheses: either male androgens were worsening viral entry, or low testosterone levels were impairing the body's immune defense.
Multiple observational hospital studies reported that men hospitalized with severe COVID-19 frequently presented with significantly lower serum testosterone levels than men with mild symptoms. Some commentators quickly concluded that low testosterone caused the severe illness, suggesting that hormone therapy might serve as a protective treatment.
This conclusion misinterprets the fundamental difference between correlation and causation. When the human body faces severe acute illness, major trauma, sepsis, or intense systemic inflammation, the hypothalamic-pituitary-gonadal (HPG) axis downregulates rapidly. Pro-inflammatory cytokines, including IL-6 and TNF-alpha, act directly on the brain and testes to suppress hormone production.
In this clinical context, low testosterone is an expected physiological consequence of critical illness, acting as a biomarker of systemic distress rather than the underlying cause of infection severity. Measuring low hormones during acute hospitalization does not indicate that the patient had low testosterone prior to becoming infected. Those interested in how hormone assessments are structured can read about testosterone testing and biomarkers.
To test these hypotheses rigorously, medical researchers conducted controlled clinical trials rather than relying on observational associations.
The HITCH randomized clinical trial evaluated whether temporarily suppressing androgen signaling with the medication degarelix would protect hospitalized men against severe COVID-19 complications. The trial enrolled 96 hospitalized male patients, randomizing them to receive either degarelix or standard care. The trial demonstrated that androgen suppression did not improve the composite clinical endpoint of mortality, continued hospitalization, or the requirement for mechanical ventilation at day 15. While this trial tested hormone suppression rather than testosterone replacement, it demonstrated that acutely altering androgen pathways does not reliably alter clinical outcomes during active viral infection.
On the other hand, researchers also evaluated whether being on testosterone therapy altered the risk of contracting the virus. A secondary analysis of a large randomized trial evaluated the three-year incidence of COVID-19 among men assigned to receive either testosterone replacement therapy or a matching placebo. The analysis showed no significant difference in infection rates between groups: 8.0% of men in the testosterone group contracted the virus compared to 8.6% of men in the placebo group (P = 0.823).
Furthermore, large observational studies tracking men who were already receiving testosterone therapy at the time of infection found no statistically significant difference in rates of hospitalization, thromboembolic events, or death compared to matched controls not receiving hormone therapy. The totality of this research confirms that testosterone therapy does not protect against viral respiratory infections, nor does it serve as an acute medical intervention for infectious illness.
When evaluating immune health and hormone status, clinicians review specific laboratory blood markers. Understanding what these biomarkers represent, and their inherent diagnostic limitations, helps prevent misinterpretation.
Total testosterone measures the entire pool of testosterone circulating in the bloodstream. This includes hormone bound tightly to sex hormone-binding globulin (SHBG), hormone bound loosely to albumin, and unbound free hormone.
A standard total testosterone measurement reflects endocrine output from the testes and adrenal glands. However, an isolated total testosterone number does not provide information about how local immune cells are processing androgens within specific peripheral tissues.
Free testosterone accounts for the approximately 1% to 2% of circulating hormone that is completely unattached to blood proteins. Bioavailable testosterone combines this free fraction with the fraction bound loosely to albumin, representing the hormone readily accessible for tissue uptake.
While free testosterone is critical for evaluating clinical hypogonadism, changes in free testosterone have not been validated as a measurement of immune system competence or infection risk.
SHBG is a glycoprotein produced by the liver that binds tightly to testosterone and estradiol, regulating their transport and availability to tissues.
Circulating SHBG levels change in response to metabolic and inflammatory states. Chronic low-grade inflammation, insulin resistance, and liver dysfunction frequently alter SHBG concentrations, which secondarily shifts the ratio of free to total testosterone without signaling an intrinsic immune defect.
None of these circulating immune markers are recommended by medical guidelines for diagnosing testosterone deficiency or monitoring the safety of hormone replacement therapy. You can read more about evaluating these parameters in our resource on testosterone testing and biomarkers.
Because the internet contains conflicting claims regarding hormones and immunity, understanding established medical standards is essential. Major medical bodies, including the Endocrine Society, maintain clear, evidence-based criteria for the diagnosis and management of male hypogonadism.
Testosterone replacement therapy is not an elective lifestyle intervention, an anti-aging remedy, or an immune wellness strategy. Clinical guidelines state that hormone therapy is indicated solely for men who meet two distinct criteria:
A patient presenting with vague, non-specific symptoms, such as recurrent winter colds, generalized fatigue, or mild joint stiffness, does not meet the diagnostic threshold for hypogonadism. Using hormone therapy to treat non-specific immune complaints in men with normal endogenous hormone levels carries documented health risks without proven medical benefit. Readers navigating symptoms can consult our guide to low testosterone signs, causes, and risk factors.
To maintain clarity regarding clinical capabilities, the medical evidence regarding testosterone and immune function can be summarized plainly:
When a qualified clinician diagnoses hypogonadism and initiates testosterone replacement therapy, standard monitoring protocols focus on safety, symptom resolution, and endocrine balance. Monitoring is not designed to measure or optimize immune markers.
According to Endocrine Society guidelines, clinical monitoring includes:
These clinical monitoring steps exist to ensure that hormone therapy remains safe and physiologically balanced. They are not intended as protocols for managing immune function. For a comprehensive overview of testing, see our section on low testosterone.
If you have concerns about your hormone levels, persistent fatigue, or general immune health, having an organized conversation with your doctor is the most effective next step. The following questions provide a constructive framework for your appointment:
Review this guide whenever you encounter commercial advertisements claiming that hormone replacement therapy can boost immunity, prevent viral illness, or treat inflammatory conditions. You may also want to revisit this material if you receive unexpected hormone or inflammatory blood test results, ensuring you evaluate the data through an objective, evidence-based lens before making health decisions.
Scientific research shows that testosterone interacts with immune cells in complex ways, but these biological mechanisms do not make hormone therapy a substitute for established medical care.
Testostra explains testosterone biology, testing, symptoms, lifestyle factors and TRT with careful sourcing and clear clinical limits.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra
